← Leaderboards
Bradley F Boeve
Mayo Clinic Rochester
$76,855,509
Attributed
$94,365,006
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $42.9M · FY2005–25$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$214,697,768 · 15
By mechanism
U19$166,820,550 · 8
U01$33,840,391 · 2
P30$9,837,573 · 2
P50$2,945,751 · 1
R34$1,178,603 · 1
R13$74,900 · 1
Top collaborators
- Howard J Rosen19 shared
- Adam L Boxer13 shared
- Kejal Kantarci9 shared
- Yo-El S Ju7 shared
- Ronald Postuma4 shared
- Ronald C Petersen2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Scott H Kaufmann$29,002,745
- Carlos B Mantilla$9,702,168
- William W Seeley$26,843,727
- Jinghua Hu$8,003,740
- James L. Kirkland$27,302,366
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseNeuroimagingParticipantProgramsClinical TrialsSiteEnrollmentGeneticSamplingS Disease Related DementiaBiological MarkersCohortImageCommunitiesResearch PersonnelInfrastructureFrontotemporal DementiaFrontotemporal Lobar DegenerationsProtocols DocumentationRecruitNeurodegenerative DisordersScanningEvaluation
Grant awards (67)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)$16,947,844
U19 · FY2025 · AG · contact PI
Clinical Core$8,988,742
U19 · FY2025 · AG · contact PI
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)$6,952,731
U19 · FY2025 · AG
Mayo Alzheimer's Disease Research Center$4,509,334
P30 · FY2025 · AG · contact PI
Longitudinal Imaging Biomarkers of Prodromal DLB$2,340,234
U01 · FY2025 · NS
Administrative Core$2,107,183
U19 · FY2025 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)$331,127
U19 · FY2025 · AG · contact PI
NAPS2 Clinical Core$289,898
U19 · FY2025 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)$174,552
U19 · FY2025 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)$123,012
U19 · FY2025 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2)$89,338
U19 · FY2025 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)$13,195,325
U19 · FY2024 · AG · contact PI
Clinical Core$7,614,416
U19 · FY2024 · AG · contact PI
Mayo Alzheimer's Disease Research Center$4,509,334
P30 · FY2024 · AG
Longitudinal Imaging Biomarkers of Prodromal DLB$2,339,366
U01 · FY2024 · NS
Administrative Core$899,292
U19 · FY2024 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)$12,618,678
U19 · FY2023 · AG · contact PI
Clinical Core$7,709,141
U19 · FY2023 · AG · contact PI
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)$7,100,969
U19 · FY2023 · AG
Longitudinal Imaging Biomarkers of Prodromal DLB$2,355,912
U01 · FY2023 · NS
Administrative Core$899,291
U19 · FY2023 · AG · contact PI
NAPS2 Clinical Core$280,699
U19 · FY2023 · AG · contact PI
Research Education Component$170,461
P30 · FY2023 · AG · contact PI
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)$7,016,272
U19 · FY2022 · AG
Longitudinal Imaging Biomarkers of Prodromal DLB$2,425,965
U01 · FY2022 · NS
NAPS2 Clinical Core$280,628
U19 · FY2022 · AG · contact PI
Research Education Component$176,691
P30 · FY2022 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)$13,002,977
U19 · FY2021 · AG · contact PI
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)$7,732,841
U19 · FY2021 · AG
Clinical Core$7,627,451
U19 · FY2021 · AG · contact PI
Longitudinal Imaging Biomarkers of Disease Progression in DLB$1,359,564
U01 · FY2021 · NS
Administrative Core$899,292
U19 · FY2021 · AG · contact PI
NAPS2 Clinical Core$307,321
U19 · FY2021 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)$221,979
U19 · FY2021 · AG · contact PI
Research Education Component$157,251
P30 · FY2021 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)$12,228,673
U19 · FY2020 · AG · contact PI
Clinical Core$7,531,603
U19 · FY2020 · AG · contact PI
Longitudinal Imaging Biomarkers of Disease Progression in DLB$1,411,504
U01 · FY2020 · NS
Administrative Core$899,291
U19 · FY2020 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - (Remote Monitoring FTLD Supplement)$419,685
U19 · FY2020 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)$393,850
U19 · FY2020 · AG · contact PI
Clinical Core$236,690
U19 · FY2020 · AG · contact PI
Research Education Component$157,251
P30 · FY2020 · AG · contact PI
Administrative Core$24,882
U19 · FY2020 · AG · contact PI
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)$12,764,241
U19 · FY2019 · AG · contact PI
Clinical Core$7,862,590
U19 · FY2019 · AG · contact PI
Longitudinal Imaging Biomarkers of Disease Progression in DLB$1,423,921
U01 · FY2019 · NS
Administrative Core$1,048,046
U19 · FY2019 · AG · contact PI
Neuroprotective Treatment Trial Planning in REM Sleep Behavior Disorder$424,342
R34 · FY2019 · AG
Neuroprotective Treatment Trial Planning in REM Sleep Behavior Disorder$342,752
R34 · FY2019 · AG
Research Education Component$157,251
P30 · FY2019 · AG · contact PI
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)$3,071,169
U01 · FY2018 · AG · contact PI
Longitudinal Imaging Biomarkers of Disease Progression in DLB$1,436,340
U01 · FY2018 · NS
Neuroprotective Treatment Trial Planning in REM Sleep Behavior Disorder$411,509
R34 · FY2018 · AG
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)$295,054
U01 · FY2018 · AG · contact PI
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)$3,395,382
U01 · FY2017 · AG · contact PI
Longitudinal Imaging Biomarkers of Disease Progression in DLB$1,808,319
U01 · FY2017 · NS
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)$3,387,606
U01 · FY2016 · AG · contact PI
International Dementia with Lewy Bodies (DLB) Conference$49,900
R13 · FY2016 · NS · contact PI
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)$3,402,147
U01 · FY2015 · AG · contact PI
International Dementia with Lewy Bodies (DLB) Conference$25,000
R13 · FY2015 · NS · contact PI
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)$3,387,908
U01 · FY2014 · AG · contact PI
CORE--CLINICAL$625,734
P50 · FY2008 · AG · contact PI
CORE--CLINICAL$627,570
P50 · FY2007 · AG · contact PI
CORE--CLINICAL$570,620
P50 · FY2006 · AG · contact PI
CORE--CLINICAL$560,217
P50 · FY2005 · AG
CORE--CLINICAL$561,610
P50 · FY2004 · AG